FTC Biosimilars Workshop: Second Time’s The Charm?
This article was originally published in The Pink Sheet Daily
Executive Summary
Having failed to significantly influence the design of the federal approval pathway, the Commission is hoping to have an impact on product naming and state substitution laws.
You may also be interested in...
FDA’s Purple Book Launches Categorization Era For Biosimilars
Modeled on “Orange Book” reference guide for small molecule drugs, agency’s new publication will be a repository of exclusivity and interchangeability information.
Biosimilar Naming Fight: Could Brand Names For All Resolve The Problem?
Brand and generic drug companies continued their debate on distinguishable INNs for biosimilars during a Federal Trade Commission meeting Feb. 4.
Biologics To Get Orange Book-style Reference Guide
Color remains a mystery, but publication may come in handy soon as biosimilar sponsors are nearing the marketing application stage.